Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 268

1.

Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users.

Euler Z, VAN DEN Kerkhof TL, Kouyos RD, Tully DC, Allen TM, Trkola A, Sanders RW, Schuitemaker H, VAN Gils MJ.

Viruses. 2019 Apr 25;11(4). pii: E384. doi: 10.3390/v11040384.

2.

An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.

Bockstal V, Tiemessen MM, Achterberg R, Van Wordragen C, Knaapen AM, Serroyen J, Marissen WE, Schuitemaker H, Zahn R.

Vaccine. 2018 Nov 12;36(46):6979-6987. doi: 10.1016/j.vaccine.2018.09.068. Epub 2018 Oct 9.

3.

Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge.

Cox F, van der Fits L, Abbink P, Larocca RA, van Huizen E, Saeland E, Verhagen J, Peterson R, Tolboom J, Kaufmann B, Schuitemaker H, Barouch DH, Zahn R.

PLoS One. 2018 Aug 24;13(8):e0202820. doi: 10.1371/journal.pone.0202820. eCollection 2018.

4.

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, Chandrashekar A, Jetton D, Stephenson KE, Li W, Korber B, Tomaras GD, Montefiori DC, Gray G, Frahm N, McElrath MJ, Baden L, Johnson J, Hutter J, Swann E, Karita E, Kibuuka H, Mpendo J, Garrett N, Mngadi K, Chinyenze K, Priddy F, Lazarus E, Laher F, Nitayapan S, Pitisuttithum P, Bart S, Campbell T, Feldman R, Lucksinger G, Borremans C, Callewaert K, Roten R, Sadoff J, Scheppler L, Weijtens M, Feddes-de Boer K, van Manen D, Vreugdenhil J, Zahn R, Lavreys L, Nijs S, Tolboom J, Hendriks J, Euler Z, Pau MG, Schuitemaker H.

Lancet. 2018 Jul 21;392(10143):232-243. doi: 10.1016/S0140-6736(18)31364-3. Epub 2018 Jul 6.

5.

Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge.

van der Lubbe JEM, Huizingh J, Verspuij JWA, Tettero L, Schmit-Tillemans SPR, Mooij P, Mortier D, Koopman G, Bogers WMJM, Dekking L, Meijberg W, Kwaks T, Brandenburg B, Tolboom JTBM, Schuitemaker H, Roozendaal R, Kuipers H, Zahn RC.

NPJ Vaccines. 2018 Jul 3;3:25. doi: 10.1038/s41541-018-0063-7. eCollection 2018.

6.

Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses.

Vujadinovic M, Khan S, Oosterhuis K, Uil TG, Wunderlich K, Damman S, Boedhoe S, Verwilligen A, Knibbe J, Serroyen J, Schuitemaker H, Zahn R, Scheper G, Custers J, Vellinga J.

Vaccine. 2018 Jul 16;36(30):4462-4470. doi: 10.1016/j.vaccine.2018.06.024. Epub 2018 Jun 18.

7.

Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys.

Kang ZH, Bricault CA, Borducchi EN, Stephenson KE, Seaman MS, Pau M, Schuitemaker H, van Manen D, Wegmann F, Barouch DH.

J Virol. 2018 Jul 17;92(15). pii: e00537-18. doi: 10.1128/JVI.00537-18. Print 2018 Aug 1.

8.

Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.

Callendret B, Vellinga J, Wunderlich K, Rodriguez A, Steigerwald R, Dirmeier U, Cheminay C, Volkmann A, Brasel T, Carrion R, Giavedoni LD, Patterson JL, Mire CE, Geisbert TW, Hooper JW, Weijtens M, Hartkoorn-Pasma J, Custers J, Grazia Pau M, Schuitemaker H, Zahn R.

PLoS One. 2018 Apr 24;13(4):e0196546. doi: 10.1371/journal.pone.0196546. eCollection 2018.

9.

A comparative study between outbred and inbred rat strains for the use in in vivo IPV potency testing.

Bockstal V, Sanders B, Achterberg R, Tiemessen M, Bogaert L, Van der Meer M, Schuitemaker H, Zahn R.

Vaccine. 2018 May 17;36(21):2917-2920. doi: 10.1016/j.vaccine.2018.04.024.

PMID:
29685598
10.

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.

Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH; IPCAVD006/RV380/HIV-V-A002 Study Group .

J Infect Dis. 2018 Jul 13;218(4):633-644. doi: 10.1093/infdis/jiy212.

PMID:
29669026
11.

A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers.

Rutten L, Lai YT, Blokland S, Truan D, Bisschop IJM, Strokappe NM, Koornneef A, van Manen D, Chuang GY, Farney SK, Schuitemaker H, Kwong PD, Langedijk JPM.

Cell Rep. 2018 Apr 10;23(2):584-595. doi: 10.1016/j.celrep.2018.03.061.

12.

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.

Callendret B, Vellinga J, Wunderlich K, Rodriguez A, Steigerwald R, Dirmeier U, Cheminay C, Volkmann A, Brasel T, Carrion R, Giavedoni LD, Patterson JL, Mire CE, Geisbert TW, Hooper JW, Weijtens M, Hartkoorn-Pasma J, Custers J, Grazia Pau M, Schuitemaker H, Zahn R.

PLoS One. 2018 Feb 20;13(2):e0192312. doi: 10.1371/journal.pone.0192312. eCollection 2018. Erratum in: PLoS One. 2018 Apr 24;13(4):e0196546.

13.

Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune Response.

Vujadinovic M, Wunderlich K, Callendret B, Koning M, Vermeulen M, Sanders B, van der Helm E, Gecgel A, Spek D, de Boer K, Stalknecht M, Serroyen J, Grazia Pau M, Schuitemaker H, Zahn R, Custers J, Vellinga J.

Hum Gene Ther. 2018 Mar;29(3):337-351. doi: 10.1089/hum.2017.023. Epub 2017 Nov 30.

14.

Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform.

Salisch NC, Vujadinovic M, van der Helm E, Spek D, Vorthoren L, Serroyen J, Kuipers H, Schuitemaker H, Zahn R, Custers J, Vellinga J.

PLoS One. 2017 Mar 31;12(3):e0174728. doi: 10.1371/journal.pone.0174728. eCollection 2017.

15.

Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.

Khan S, Oosterhuis K, Wunderlich K, Bunnik EM, Bhaggoe M, Boedhoe S, Karia S, Steenbergen RDM, Bosch L, Serroyen J, Janssen S, Schuitemaker H, Vellinga J, Scheper G, Zahn R, Custers J.

Int J Cancer. 2017 Jul 15;141(2):393-404. doi: 10.1002/ijc.30679. Epub 2017 Apr 24.

16.

Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys.

Borducchi EN, Cabral C, Stephenson KE, Liu J, Abbink P, Ng'ang'a D, Nkolola JP, Brinkman AL, Peter L, Lee BC, Jimenez J, Jetton D, Mondesir J, Mojta S, Chandrashekar A, Molloy K, Alter G, Gerold JM, Hill AL, Lewis MG, Pau MG, Schuitemaker H, Hesselgesser J, Geleziunas R, Kim JH, Robb ML, Michael NL, Barouch DH.

Nature. 2016 Dec 8;540(7632):284-287. doi: 10.1038/nature20583. Epub 2016 Nov 9.

17.

An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability.

van Gils MJ, van den Kerkhof TL, Ozorowski G, Cottrell CA, Sok D, Pauthner M, Pallesen J, de Val N, Yasmeen A, de Taeye SW, Schorcht A, Gumbs S, Johanna I, Saye-Francisco K, Liang CH, Landais E, Nie X, Pritchard LK, Crispin M, Kelsoe G, Wilson IA, Schuitemaker H, Klasse PJ, Moore JP, Burton DR, Ward AB, Sanders RW.

Nat Microbiol. 2016 Nov 14;2:16199. doi: 10.1038/nmicrobiol.2016.199.

18.

HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds.

van den Kerkhof TL, de Taeye SW, Boeser-Nunnink BD, Burton DR, Kootstra NA, Schuitemaker H, Sanders RW, van Gils MJ.

Retrovirology. 2016 Jul 7;13(1):48. doi: 10.1186/s12977-016-0279-4.

19.

Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies.

van den Kerkhof TL, van Gils MJ, Boeser-Nunnink BD, Burger JA, Schuitemaker H, Sanders RW.

AIDS. 2016 Sep 10;30(14):2179-84. doi: 10.1097/QAD.0000000000001177.

PMID:
27258397
20.

Correction: Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination.

Mahan AE, Jennewein MF, Suscovich T, Dionne K, Tedesco J, Chung AW, Streeck H, Pau M, Schuitemaker H, Francis D, Fast P, Laufer D, Walker BD, Baden L, Barouch DH, Alter G.

PLoS Pathog. 2016 Jun 2;12(6):e1005694. doi: 10.1371/journal.ppat.1005694. eCollection 2016 Jun.

21.

Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.

Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, Nuthall E, Voysey M, Silva-Reyes L, McElrath MJ, De Rosa SC, Frahm N, Cohen KW, Shukarev G, Orzabal N, van Duijnhoven W, Truyers C, Bachmayer N, Splinter D, Samy N, Pau MG, Schuitemaker H, Luhn K, Callendret B, Van Hoof J, Douoguih M, Ewer K, Angus B, Pollard AJ, Snape MD.

JAMA. 2016 Apr 19;315(15):1610-23. doi: 10.1001/jama.2016.4218.

PMID:
27092831
22.

Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine.

Sanders BP, de Los Rios Oakes I, van Hoek V, Bockstal V, Kamphuis T, Uil TG, Song Y, Cooper G, Crawt LE, Martín J, Zahn R, Lewis J, Wimmer E, Custers JH, Schuitemaker H, Cello J, Edo-Matas D.

PLoS Pathog. 2016 Mar 31;12(3):e1005483. doi: 10.1371/journal.ppat.1005483. eCollection 2016 Mar.

23.

Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination.

Mahan AE, Jennewein MF, Suscovich T, Dionne K, Tedesco J, Chung AW, Streeck H, Pau M, Schuitemaker H, Francis D, Fast P, Laufer D, Walker BD, Baden L, Barouch DH, Alter G.

PLoS Pathog. 2016 Mar 16;12(3):e1005456. doi: 10.1371/journal.ppat.1005456. eCollection 2016 Mar. Erratum in: PLoS Pathog. 2016 Jun;12(6):e1005694.

24.

The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype.

Cornelissen M, Euler Z, van den Kerkhof TL, van Gils MJ, Boeser-Nunnink BD, Kootstra NA, Zorgdrager F, Schuitemaker H, Prins JM, Sanders RW, van der Kuyl AC.

AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):1135-1142. Epub 2016 Feb 24.

PMID:
26910384
25.

Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes.

de Taeye SW, Ozorowski G, Torrents de la Peña A, Guttman M, Julien JP, van den Kerkhof TL, Burger JA, Pritchard LK, Pugach P, Yasmeen A, Crampton J, Hu J, Bontjer I, Torres JL, Arendt H, DeStefano J, Koff WC, Schuitemaker H, Eggink D, Berkhout B, Dean H, LaBranche C, Crotty S, Crispin M, Montefiori DC, Klasse PJ, Lee KK, Moore JP, Wilson IA, Ward AB, Sanders RW.

Cell. 2015 Dec 17;163(7):1702-15. doi: 10.1016/j.cell.2015.11.056.

26.

Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load.

McLaren PJ, Coulonges C, Bartha I, Lenz TL, Deutsch AJ, Bashirova A, Buchbinder S, Carrington MN, Cossarizza A, Dalmau J, De Luca A, Goedert JJ, Gurdasani D, Haas DW, Herbeck JT, Johnson EO, Kirk GD, Lambotte O, Luo M, Mallal S, van Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, Poli G, Sandhu MS, Schuitemaker H, Shea PR, Theodorou I, Walker BD, Weintrob AC, Winkler CA, Wolinsky SM, Raychaudhuri S, Goldstein DB, Telenti A, de Bakker PI, Zagury JF, Fellay J.

Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14658-63. doi: 10.1073/pnas.1514867112. Epub 2015 Nov 9.

27.

Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology.

Chung AW, Kumar MP, Arnold KB, Yu WH, Schoen MK, Dunphy LJ, Suscovich TJ, Frahm N, Linde C, Mahan AE, Hoffner M, Streeck H, Ackerman ME, McElrath MJ, Schuitemaker H, Pau MG, Baden LR, Kim JH, Michael NL, Barouch DH, Lauffenburger DA, Alter G.

Cell. 2015 Nov 5;163(4):988-98. doi: 10.1016/j.cell.2015.10.027.

28.

Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.

Sanders BP, Oakes Ide L, van Hoek V, Liu Y, Marissen W, Minor PD, Wimmer E, Schuitemaker H, Custers JH, Macadam A, Cello J, Edo-Matas D.

Vaccine. 2015 Nov 27;33(48):6611-6. doi: 10.1016/j.vaccine.2015.10.091. Epub 2015 Nov 1.

PMID:
26529068
29.

Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study.

van der Helm JJ, Geskus R, Lodi S, Meyer L, Schuitemaker H, Gunsenheimer-Bartmeyer B, Monforte Ad, Olson A, Touloumi G, Sabin C, Porter K, Prins M; CASCADE Collaboration in EuroCoord.

Lancet HIV. 2014 Oct;1(1):e41-8. doi: 10.1016/S2352-3018(14)70016-5. Epub 2014 Sep 18.

PMID:
26423816
30.

Identification of Genes Whose Expression Profile Is Associated with Non-Progression towards AIDS Using eQTLs.

Spadoni JL, Rucart P, Le Clerc S, van Manen D, Coulonges C, Ulveling D, Laville V, Labib T, Taing L, Delaneau O, Montes M, Schuitemaker H, Noirel J, Zagury JF.

PLoS One. 2015 Sep 14;10(9):e0136989. doi: 10.1371/journal.pone.0136989. eCollection 2015.

31.

Synthetic virus seeds for improved vaccine safety: Genetic reconstruction of poliovirus seeds for a PER.C6 cell based inactivated poliovirus vaccine.

Sanders BP, Edo-Matas D, Papic N, Schuitemaker H, Custers JHHV.

Vaccine. 2015 Oct 13;33(42):5498-5502. doi: 10.1016/j.vaccine.2015.08.081. Epub 2015 Sep 9.

PMID:
26362098
32.

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism.

Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJM, Widjojoatmodjo MN, Zahn R, Schuitemaker H, McLellan JS, Langedijk JPM.

Nat Commun. 2015 Sep 3;6:8143. doi: 10.1038/ncomms9143.

33.

Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.

Widjojoatmodjo MN, Bogaert L, Meek B, Zahn R, Vellinga J, Custers J, Serroyen J, Radošević K, Schuitemaker H.

Vaccine. 2015 Oct 5;33(41):5406-5414. doi: 10.1016/j.vaccine.2015.08.056. Epub 2015 Aug 28.

34.

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies.

McCoy LE, Falkowska E, Doores KJ, Le K, Sok D, van Gils MJ, Euler Z, Burger JA, Seaman MS, Sanders RW, Schuitemaker H, Poignard P, Wrin T, Burton DR.

PLoS Pathog. 2015 Aug 12;11(8):e1005110. doi: 10.1371/journal.ppat.1005110. eCollection 2015 Aug.

35.

Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys.

Barouch DH, Alter G, Broge T, Linde C, Ackerman ME, Brown EP, Borducchi EN, Smith KM, Nkolola JP, Liu J, Shields J, Parenteau L, Whitney JB, Abbink P, Ng'ang'a DM, Seaman MS, Lavine CL, Perry JR, Li W, Colantonio AD, Lewis MG, Chen B, Wenschuh H, Reimer U, Piatak M, Lifson JD, Handley SA, Virgin HW, Koutsoukos M, Lorin C, Voss G, Weijtens M, Pau MG, Schuitemaker H.

Science. 2015 Jul 17;349(6245):320-4. doi: 10.1126/science.aab3886. Epub 2015 Jul 2.

36.

Brunenders: a partially attenuated historic poliovirus type I vaccine strain.

Sanders BP, Liu Y, Brandjes A, van Hoek V, de Los Rios Oakes I, Lewis J, Wimmer E, Custers JH, Schuitemaker H, Cello J, Edo-Matas D.

J Gen Virol. 2015 Sep;96(9):2614-22. doi: 10.1099/vir.0.000197. Epub 2015 May 26.

PMID:
26018960
37.

Differential characteristics of cytotoxic T lymphocytes restricted by the protective HLA alleles B*27 and B*57 in HIV-1 infection.

Schellens IM, Spits HB, Navis M, Westerlaken GH, Nanlohy NM, Coffeng LE, Kootstra N, Miedema F, Schuitemaker H, Borghans JA, van Baarle D.

J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):236-45. doi: 10.1097/QAI.0000000000000324.

PMID:
25171732
38.

Low level of HIV-1 evolution after transmission from mother to child.

Gijsbers EF, van Nuenen AC, de la Peňa AT, Bowles EJ, Stewart-Jones GB, Schuitemaker H, Kootstra NA.

Sci Rep. 2014 May 28;4:5079. doi: 10.1038/srep05079.

39.

Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers.

van den Kerkhof TL, Euler Z, van Gils MJ, Boeser-Nunnink BD, Schuitemaker H, Sanders RW.

AIDS. 2014 May 15;28(8):1237-40. doi: 10.1097/QAD.0000000000000228.

PMID:
24556870
40.

Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer.

Nkolola JP, Cheung A, Perry JR, Carter D, Reed S, Schuitemaker H, Pau MG, Seaman MS, Chen B, Barouch DH.

Vaccine. 2014 Apr 11;32(18):2109-16. doi: 10.1016/j.vaccine.2014.02.001. Epub 2014 Feb 18.

41.

HIV-1 replication fitness of HLA-B*57/58:01 CTL escape variants is restored by the accumulation of compensatory mutations in gag.

Gijsbers EF, Feenstra KA, van Nuenen AC, Navis M, Heringa J, Schuitemaker H, Kootstra NA.

PLoS One. 2013 Dec 5;8(12):e81235. doi: 10.1371/journal.pone.0081235. eCollection 2013.

42.

Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys.

Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, Dugast AS, Alter G, Ferguson M, Li W, Earl PL, Moss B, Giorgi EE, Szinger JJ, Eller LA, Billings EA, Rao M, Tovanabutra S, Sanders-Buell E, Weijtens M, Pau MG, Schuitemaker H, Robb ML, Kim JH, Korber BT, Michael NL.

Cell. 2013 Oct 24;155(3):531-9. doi: 10.1016/j.cell.2013.09.061. Epub 2013 Oct 24.

43.

HIV-1 isolation from infected peripheral blood mononuclear cells.

Dispinseri S, Saba E, Vicenzi E, Kootstra NA, Schuitemaker H, Scarlatti G.

Methods Mol Biol. 2014;1087:187-96. doi: 10.1007/978-1-62703-670-2_15.

PMID:
24158823
44.

The presence of CXCR4-using HIV-1 prior to start of antiretroviral therapy is an independent predictor of delayed viral suppression.

Gijsbers EF, van Sighem A, Harskamp AM, Welkers MR, de Wolf F, Brinkman K, Prins JM, Schuitemaker H, van 't Wout AB, Kootstra NA.

PLoS One. 2013 Oct 1;8(10):e76255. doi: 10.1371/journal.pone.0076255. eCollection 2013.

45.

HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.

van den Kerkhof TL, Feenstra KA, Euler Z, van Gils MJ, Rijsdijk LW, Boeser-Nunnink BD, Heringa J, Schuitemaker H, Sanders RW.

Retrovirology. 2013 Sep 23;10:102. doi: 10.1186/1742-4690-10-102.

46.

HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.

Malherbe DC, Sanders RW, van Gils MJ, Park B, Gomes MM, Schuitemaker H, Barnett S, Haigwood NL.

PLoS One. 2013 Sep 9;8(9):e75277. doi: 10.1371/journal.pone.0075277. eCollection 2013.

47.

Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.

Heyndrickx L, Stewart-Jones G, Jansson M, Schuitemaker H, Bowles E, Buonaguro L, Grevstad B, Vinner L, Vereecken K, Parker J, Ramaswamy M, Biswas P, Vanham G, Scarlatti G, Fomsgaard A; NGIN Consortium.

PLoS One. 2013 Sep 2;8(9):e74552. doi: 10.1371/journal.pone.0074552. eCollection 2013.

48.

Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls.

McLaren PJ, Coulonges C, Ripke S, van den Berg L, Buchbinder S, Carrington M, Cossarizza A, Dalmau J, Deeks SG, Delaneau O, De Luca A, Goedert JJ, Haas D, Herbeck JT, Kathiresan S, Kirk GD, Lambotte O, Luo M, Mallal S, van Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, O'Brien SJ, Pereyra F, Plummer FA, Poli G, Qi Y, Rucart P, Sandhu MS, Shea PR, Schuitemaker H, Theodorou I, Vannberg F, Veldink J, Walker BD, Weintrob A, Winkler CA, Wolinsky S, Telenti A, Goldstein DB, de Bakker PI, Zagury JF, Fellay J.

PLoS Pathog. 2013;9(7):e1003515. doi: 10.1371/journal.ppat.1003515. Epub 2013 Jul 25.

49.

Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.

Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondi A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE; MAGNIFICENT Consortium; INSIGHT; Swiss HIV Cohort Study.

Clin Infect Dis. 2013 Jul;57(1):112-21. doi: 10.1093/cid/cit196. Epub 2013 Mar 26.

50.

Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals.

Euler Z, van Gils MJ, Boeser-Nunnink BD, Schuitemaker H, van Manen D.

PLoS One. 2013;8(1):e54684. doi: 10.1371/journal.pone.0054684. Epub 2013 Jan 23.

Supplemental Content

Loading ...
Support Center